Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | FECH | P22830 | 1/20 | 0.57 |
| ▸ | CLK3 | P49761 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 10/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123311 | 1.00 | PLK1 (0.59) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1636188 | 0.85 | PLK1 (0.51) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2422243 | 0.85 | PLK1 (0.58) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3230061 | 0.85 | F10 (0.49) | F10NPC1RAB9APOLBLMNA | |
| SCHEMBL15080218 | 0.85 | PLK1 (0.68) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1122896 | 0.84 | PLK1 (0.67) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1122895 | 0.84 | PLK1 (0.67) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1123199 | 0.84 | PLK1 (0.70) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1123201 | 0.84 | PLK1 (0.70) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1123076 | 0.83 | PLK1 (0.68) | PLK1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | claimed |
| EP-1773353-B1 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | claimed |
| US-20100152096-A1 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF AMINO-SUBSTITUTED (E)-2, 6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS, INC | 2010-06-17 | — | — | US | claimed |
| EP-2124569-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES | Onconova Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | claimed |
| US-20090036462-A1 | Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2009-02-05 | — | — | US | claimed |
| WO-2008088803-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1773353-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | Onconova Therapeutics, Inc (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006010152-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | claimed |
| US-8476320-B2 | Formulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones | ONCONOVA THERAPEUTICS, INC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8324190-B2 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | Temple University—Of the Commonwealth System of Higher Education (US) | 2012-12-04 | — | — | US | disclosed |
| US-8063109-B2 | Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1487428-B1 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1773353-B1 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7598232-B2 | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090036462-A1 | Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones | ONCONOVA THERAPEUTICS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2008088803-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281066-A1 | Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones | CCNY, CCND2, ETV6 | PLK1 1292/4885HDAC3 3299/4885HDAC4 2323/4885 |
| US-20090036462-A1 | Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones | PKN2, GYS2, DHPS | PLK1 1494/4885HDAC3 4404/4885HDAC4 4325/4885 |
| US-20100152096-A1 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF AMINO-SUBSTITUTED (E)-2, 6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES | PKN2, DHPS, GYS2 | PLK1 1608/4885HDAC3 4638/4885HDAC4 4549/4885 |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | CCNY, CCND2, CCNB1 | PLK1 1376/4885HDAC3 3434/4885HDAC4 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.